Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Agreement to develop E. coli O157:H7 vaccine
Researchers at work on the project in the Roslin Institute
Collaborative research enters commercial phase

Roslin Technologies has signed an agreement with animal sciences research establishments Moredun Research Institute, Scotland’s Rural College and the Roslin Institute at the University of Edinburgh, to fund the commercial development of an E. coli O157:H7 vaccine for cattle, which it is claimed will prevent illness in humans.

E. coli O157:H7 is a pathogenic bacterium of cattle that can cause life-threatening food-borne illness in humans through the consumption of contaminated products, such as dairy products and meat. Despite efforts to reduce contamination of food, E. coli O157:H7 causes one to 10 cases per 100,000 people, with certain countries having clusters of more virulent strains – notably the UK, USA, Argentina and Sweden.
 
The experimental vaccine has been developed to limit E. coli O157:H7 shedding from – and transmission between – cattle. Although the bacteria do not harm cattle, farmers will be encouraged to vaccinate animals against infection with this new vaccine. Early results have indicated that this vaccine may be more effective than other previous attempts and have a greater impact in reducing human exposure and infection.

The project team has been led by Dr Simon Wheeler COO of Roslin Technologies, with significant input from the principal investigators, Professor David Gally from Roslin Institute and Dr Tom McNeilly from Moredun Research Institute, who have been doing the fundamental research necessary to really understand whether the vaccine works and the essential science behind it.

Under the new agreement, Roslin Technologies will perform a two-step validation trial from May  to September 2020 in Nebraska, USA. The field trials will examine ‘super-shedding’ in cattle to discover whether the vaccine prevents shedding of the bacteria and is viable for commercial use.
 
The background research was funded  in part by UK agencies Defra (Department for Environment, Food & Rural Affairs), BBSRC (Biotechnology and Biological Sciences Research Council, FSA/FSS (Food Standards Agency/Food Standards Scotland), and other commercial partners. This valuable contribution is recognised by the project team.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.